Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen, Leo Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H. T. Lim, Matthijs C. Brouwer, Pieter R. Tuinman, José Francisco Kerr Saraiva,

The Lancet Respiratory Medicine · 2022 · 142 citations · 21 references

DOIFull text

Open access

Concepts

References

21